Fulltext

Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates

Berchtold, André ; Michaud, Pierre-André ; Nardelli-Haefliger, Denise ; Surís, Joan-Carles

In: International Journal of Public Health, 2010, vol. 55, no. 1, p. 25-34

Ajouter à la liste personnelle
    Titre
    • Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates
    Auteur
    • Berchtold, André. Groupe de Recherche sur la Santé des Adolescents (GRSA), University Hospital Center and University of Lausanne, Lausanne, Switzerland
    • Michaud, Pierre-André. Groupe de Recherche sur la Santé des Adolescents (GRSA), University Hospital Center and University of Lausanne, Lausanne, Switzerland
    • Nardelli-Haefliger, Denise. Institut de Microbiologie, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    • Surís, Joan-Carles. Groupe de Recherche sur la Santé des Adolescents (GRSA), University Hospital Center and University of Lausanne, Lausanne, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • International Journal of Public Health, 2010, vol. 55, no. 1, p. 25-34. SP Birkhäuser Verlag Basel
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:311019
    Summary
    Objectives: Human papillomavirus (HPV) is a sexually transmitted infection of particular interest because of its high prevalence rate and strong causal association with cervical cancer. Two prophylactic vaccines have been developed and different countries have made or will soon make recommendations for the vaccination of girls. Even if there is a consensus to recommend a vaccination before the beginning of sexual activity, there are, however, large discrepancies between countries concerning the perceived usefulness of a catch-up procedure and of boosters. The main objective of this article is to simulate the impact on different vaccination policies upon the mid- and long-term HPV 16/18 age-specific infection rates. Methods: We developed an epidemiological model based on the susceptible-infective-recovered approach using Swiss data. The mid- and long-term impact of different vaccination scenarios was then compared. Results: The generalization of a catch-up procedure is always beneficial, whatever its extent. Moreover, pending on the length of the protection offered by the vaccine, boosters will also be very useful. Conclusions: To be really effective, a vaccination campaign against HPV infection should at least include a catch-up to early reach a drop in HPV 16/18 prevalence, and maybe boosters. Otherwise, the protection insured for women in their 20s could be lower than expected, resulting in higher risks to later develop cervical cancer